logo
logo

Alpha Healthcare Acquisition Corp. Iii Announces Non-Binding Letter Of Intent To Acquire A Commercial Stage Regenerative Medicine Company Conditioned Upon Closing Of Carmell Business Combination

Jun 27, 2023about 2 years ago

Acquiring Company

Alpha Healthcare Acquisition III

Acquired Company

Stage Regenerative Medicine

Description

Alpha Healthcare Acquisition Corp. III (Nasdaq: ALPA) (“ALPA”), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced the execution of a non-binding letter of intent (the “LOI”) to acquire a commercial stage regenerative medicine company (the “Target”) conditioned upon the closing of ALPA’s initial business combination with Carmell Therapeutics Corporation, a Phase 2 stage regenerative medicine platform company developing allogeneic plasma-based biomaterials for active soft tissue repair, aesthetics and orthopedic indications (“Carmell”).

Company Information

Company

Alpha Healthcare Acquisition III

DealWatch™ Score

66
High M&A Activity

M&A Opportunity Analysis

Get personalized insights on M&A opportunities

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed